Captopril does not affect plasma endothelin-1 during thrombolysis and reperfusion

Area of Science:

• Cardiology
• Pharmacology

Background:

• Endothelin-1 (ET-1) levels are elevated in acute myocardial infarction (AMI).
• Experimental data suggest captopril may reduce ET-1 secretion, and ET-1 increases during reperfusion.

Purpose of the Study:

• To investigate whether captopril administration reduces plasma ET-1 levels during thrombolysis in patients with AMI.

Main Methods:

• A double-blind, randomized study involving 73 patients with suspected AMI receiving thrombolysis.
• Patients received either captopril (6.25 mg orally) or placebo 15 minutes before thrombolysis.
• Plasma ET-1 levels were measured at baseline, 1 hour, and 2 hours post-thrombolysis.

Main Results:

• No significant differences in plasma ET-1 concentrations were observed between the captopril and placebo groups at any time point.
• Mean ET-1 levels showed no significant reduction in the captopril group compared to placebo across unstable angina, inferior AMI, and anterior AMI subgroups.
• While anterior AMI showed a significant increase in ET-1 from baseline to 2 hours in both groups, captopril did not alter this trend.

Conclusions:

• Captopril administration does not appear to affect plasma endothelin-1 levels in patients undergoing thrombolysis for acute myocardial infarction.
• The findings do not support a role for captopril in modulating ET-1 during the reperfusion phase of AMI treatment.